Skip to main content

Table 1 Markers of bone turnover and calcium homeostasis during r-hPRL or placebo treatment

From: Short-term prolactin administration causes expressible galactorrhea but does not affect bone turnover: pilot data for a new lactation agent

  Placebo r-hPRL
  Before treatment After treatment Before treatment After treatment
Deoxypyridinoline (nM/mM) 7.2 ± 0.6 6.9 ± 0.7 9.5 ± 2.1 7.4 ± 1.8
N-telopeptide (nM/mM Cr) 45.3 ± 4.6 42.3 ± 5.6 35.6 ± 4.0 31.9 ± 4.1
Bone specific alk phos (U/L) 15.4 ± 1.3 17.5 ± 1.5* 17.0 ± 2.2 18.1 ± 2.5
Calcium (mmol/L) 2.3 ± 0.03 2.4 ± 0.03* 2.3 ± 0.03 2.4 ± 0.03*
Albumin (g/L) 40 ± 1 43 ± 1* 40 ± 1 42 ± 1
Corrected calcium (mmol/L) 2.4 ± 0.03 2.4 ± 0.03 2.4 ± 0.03 2.5 ± 0.05
Phosphorus (mmol/L) 1.2 ± 0.03 1.1 ± 0.03 1.0 ± 0.06 1.1 ± 0.06
PTH (ng/L) 45.7 ± 4.4 47.6 ± 4.5 46.8 ± 5.9 38.8 ± 6.2
PTH-rP (pmol/L) 0.33 ± 0.02 0.35 ± 0.04 0.30 ± 0.00 0.37 ± 0.05
1,25-(OH) 2 Vit D (pmol/L) 102.2 ± 7.0 102.2 ± 6.7 115.4 ± 17.5 117.6 ± 25.2
Urinary Ca/Cr 0.11 ± 0.02 0.11 ± 0.02 0.10 ± 0.02 0.15 ± 0.02
Urinary Phos/Cr 0.61 ± 0.07 0.61 ± 0.08 0.60 ± 0.07 0.59 ± 0.05
  1. All results: mean ± SE
  2. * p < 0.05 within a group as indicated by the Tukey post hoc test.